Zacks Research Brokers Raise Earnings Estimates for CRL

Charles River Laboratories International, Inc. (NYSE:CRL) – Analysts at Zacks Research raised their Q4 2025 EPS estimates for Charles River Laboratories International in a note issued to investors on Monday, February 2nd. Zacks Research analyst Team now anticipates that the medical research company will post earnings of $2.32 per share for the quarter, up from their previous estimate of $2.31. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $9.36 per share. Zacks Research also issued estimates for Charles River Laboratories International’s Q1 2026 earnings at $2.39 EPS, Q4 2026 earnings at $2.92 EPS, Q1 2027 earnings at $2.43 EPS and Q4 2027 earnings at $3.25 EPS.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, November 5th. The medical research company reported $2.43 earnings per share for the quarter, beating analysts’ consensus estimates of $2.32 by $0.11. Charles River Laboratories International had a positive return on equity of 15.78% and a negative net margin of 2.07%.The business had revenue of $1 billion for the quarter, compared to analyst estimates of $990.43 million. During the same period in the prior year, the company earned $2.59 earnings per share. The company’s revenue was down .5% on a year-over-year basis.

Several other brokerages also recently weighed in on CRL. Argus set a $200.00 target price on Charles River Laboratories International in a research note on Monday, November 17th. Bank of America upgraded shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price objective for the company in a research report on Monday, December 15th. Barclays increased their price objective on shares of Charles River Laboratories International from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Citigroup boosted their target price on shares of Charles River Laboratories International from $200.00 to $265.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Finally, Mizuho set a $215.00 price target on shares of Charles River Laboratories International in a research note on Friday, January 9th. Ten analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $209.46.

Charles River Laboratories International Trading Down 8.9%

Shares of NYSE:CRL opened at $183.58 on Wednesday. The company has a current ratio of 1.37, a quick ratio of 1.10 and a debt-to-equity ratio of 0.64. Charles River Laboratories International has a 12-month low of $91.86 and a 12-month high of $228.88. The business has a 50 day moving average of $204.11 and a two-hundred day moving average of $179.49. The company has a market capitalization of $9.03 billion, a PE ratio of -117.68, a PEG ratio of 6.04 and a beta of 1.63.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its stake in Charles River Laboratories International by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 5,887,175 shares of the medical research company’s stock worth $1,174,374,000 after acquiring an additional 47,432 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in Charles River Laboratories International by 29.1% during the second quarter. Allspring Global Investments Holdings LLC now owns 2,291,126 shares of the medical research company’s stock worth $353,750,000 after purchasing an additional 516,521 shares during the period. Ariel Investments LLC lifted its position in shares of Charles River Laboratories International by 28.6% during the second quarter. Ariel Investments LLC now owns 1,415,348 shares of the medical research company’s stock worth $214,751,000 after purchasing an additional 314,572 shares in the last quarter. Invesco Ltd. boosted its stake in shares of Charles River Laboratories International by 1.0% in the third quarter. Invesco Ltd. now owns 1,249,178 shares of the medical research company’s stock valued at $195,446,000 after purchasing an additional 12,035 shares during the period. Finally, Bank of America Corp DE grew its holdings in shares of Charles River Laboratories International by 13.4% in the third quarter. Bank of America Corp DE now owns 1,163,348 shares of the medical research company’s stock valued at $182,017,000 after purchasing an additional 137,335 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.